title: The use of recombinant-activated factor VII in von Willebrand disease: a case series.
abstract: Spontaneous and surgery-associated bleeding in patients with von Willebrand disease (vWD) cannot always be controlled with desmopressin or replacement therapy. This paper presents results on the use of recombinant-activated factor VII (rFVIIa) in patients with vWD included in the internet registry Haemostasis.com. Twenty-eight reports on the use of rFVIIa in vWD were identified from the database and included in this analysis. The bleeding episodes were classified as mild (n = 7), moderate (n = 16), or severe (n = 2), and were unspecified in three cases. The median dose of rFVIIa administered was 94 microg/kg body weight (40-127.3 microg/kg). Bleeding stopped in 23 of 27 evaluable patients (85%) and markedly decreased in three patients; the total response rate was 96% (26/27 patients). Response did not correlate with the type of vWD, the site or severity of the initial bleed, or the rFVIIa dose. Other replacement therapies were infrequently used, and their use was similar in the 24 h before and after rFVIIa administration. Eighteen patients also received antifibrinolytic treatment, but its impact on response was not recorded. Only one adverse event (mild fever) was observed. These cases suggest a role for rFVIIa as a safe and effective therapy for vWD.
authors.affiliation: Werlhof-Institute for Haemostasis and Thrombosis, Hannover, Germany. mail@werlhof-institut.de
authors.forename: Mario
authors.initials: M
authors.lastname: von Depka
authors.forename: Murtada
authors.initials: M
authors.lastname: Hassan
authors.forename: Jan
authors.initials: J
authors.lastname: Blatnŷ
authors.forename: Petr
authors.initials: P
authors.lastname: Smejkal
authors.forename: Vladimir
authors.initials: V
authors.lastname: Vdovin
mesh_terms: D000293:Adolescent; D000328:Adult; D000933:Antifibrinolytic Agents / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions; D005169:Factor VIII / Q000008:administration & dosage; D015942:Factor VIIa / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000188:drug therapy*
chemical_list: D000933:Antifibrinolytic Agents; D011994:Recombinant Proteins; D005169:Factor VIII; D015942:Factor VIIa